WO2004092738A3 - Assay for modulators of e2f-1 phosphorylation - Google Patents

Assay for modulators of e2f-1 phosphorylation Download PDF

Info

Publication number
WO2004092738A3
WO2004092738A3 PCT/GB2004/001631 GB2004001631W WO2004092738A3 WO 2004092738 A3 WO2004092738 A3 WO 2004092738A3 GB 2004001631 W GB2004001631 W GB 2004001631W WO 2004092738 A3 WO2004092738 A3 WO 2004092738A3
Authority
WO
WIPO (PCT)
Prior art keywords
chk2
activity
phosphorylation
role
modulators
Prior art date
Application number
PCT/GB2004/001631
Other languages
French (fr)
Other versions
WO2004092738A2 (en
Inventor
Thangue Nicholas Barrie La
Craig Stevens
Original Assignee
Univ Glasgow
Thangue Nicholas Barrie La
Craig Stevens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow, Thangue Nicholas Barrie La, Craig Stevens filed Critical Univ Glasgow
Publication of WO2004092738A2 publication Critical patent/WO2004092738A2/en
Publication of WO2004092738A3 publication Critical patent/WO2004092738A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the finding that Chk2 functions as a key effector of E2F-1 induction during DNA damage. The regulation of E2F-1 activity through the DNA damage signalling pathway and specifically by Chk2, implies a role for E2F-1 in checkpoint control. Such a role for E2F-1 may contribute to the tumour suppressor activity of E2F-1. This finding gives rise to assays, methods and means for determining the activity of Chk2 and identifying modulators of E2F-1 phosphorylation by Chk2 as provided herein.
PCT/GB2004/001631 2003-04-15 2004-04-15 Assay for modulators of e2f-1 phosphorylation WO2004092738A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308711.1 2003-04-15
GB0308711A GB0308711D0 (en) 2003-04-15 2003-04-15 Assay methods

Publications (2)

Publication Number Publication Date
WO2004092738A2 WO2004092738A2 (en) 2004-10-28
WO2004092738A3 true WO2004092738A3 (en) 2005-03-24

Family

ID=9956835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001631 WO2004092738A2 (en) 2003-04-15 2004-04-15 Assay for modulators of e2f-1 phosphorylation

Country Status (2)

Country Link
GB (1) GB0308711D0 (en)
WO (1) WO2004092738A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871901A (en) * 1994-07-01 1999-02-16 Medical Research Council Assay for inhibitors of DP-1 and other DP proteins
US20020028487A1 (en) * 1997-10-21 2002-03-07 The University Court Of The University Of Glasgow JMY, a co-activator for p300/CBP, nucleic acid encoding JMY and uses thereof
US20020147145A1 (en) * 2000-03-08 2002-10-10 Zealand Pharmaceuticals A/S Materials and methods relating to the degradation of Cdc25A in response to DNA damage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871901A (en) * 1994-07-01 1999-02-16 Medical Research Council Assay for inhibitors of DP-1 and other DP proteins
US20020028487A1 (en) * 1997-10-21 2002-03-07 The University Court Of The University Of Glasgow JMY, a co-activator for p300/CBP, nucleic acid encoding JMY and uses thereof
US20020147145A1 (en) * 2000-03-08 2002-10-10 Zealand Pharmaceuticals A/S Materials and methods relating to the degradation of Cdc25A in response to DNA damage

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STEVENS C. ET AL.: "Chk2 activates E2F-1 in response to DNA damage.", NATURE CELL BIOLOGY, vol. 5, 22 April 2003 (2003-04-22), pages 401 - 409, XP002309315 *
STEVENS C. ET AL.: "E2F and cell cycle control : a double-edged sword.", ARCH. BIOCHEM. BIOPHYS., vol. 412, 19 March 2003 (2003-03-19), pages 157 - 169, XP002309314 *
STEVENS C. ET AL.: "The emerging role of E2F-1 in the DNA damage response and checkpoint control.", DNA REPAIR, vol. 3, August 2004 (2004-08-01), pages 1071 - 1079, XP002309316 *

Also Published As

Publication number Publication date
GB0308711D0 (en) 2003-05-21
WO2004092738A2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
WO2002010210A3 (en) Polypeptides for identifying herbicidally active compounds
WO2008091954A3 (en) Optimized cd40 antibodies and methods of using the same
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
WO2006038208A3 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
WO2006017274A3 (en) Systems and methods for sample modification using fluidic chambers
WO2003050295A3 (en) Assays and implements for determining and modulating hsp90 binding activity
WO2008073161A3 (en) Hemagglutinin polypeptides, and reagents and methods relating thereto
HK1126856A1 (en) Methods for identifying polypeptide targets
WO2006012391A3 (en) Devices and methods for communicating with a microcontroller
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2005028678A3 (en) Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
WO2010126590A8 (en) Ptp1b inhibitors
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
NO20072293L (en) Lightweight building plate, as well as methods for making it
EG24819A (en) Alkylation process with settler effluent recycle.
WO2006017748A3 (en) Materials and methods for identifying anti-schizophrenic agents
WO2004092738A3 (en) Assay for modulators of e2f-1 phosphorylation
WO2007038331A8 (en) Novel chemical compounds
WO2006127458A3 (en) Novel chemical compounds
WO2006060335A3 (en) Cellular signaling pathway based assays, reagents and kits
WO2005034840A8 (en) Identification of kinase inhibitors
WO2008076916A3 (en) Thallium-sensitive agents and methods of using the same
WO2006020016A3 (en) Myd88 as a therapeutic target for cancer
DK1685098T3 (en) Ortho-substituted pentafluorosulfanyl benzols, process for their preparation and their use as valuable synthetic intermediates
WO2005003388A3 (en) Fluorescence assays for nucleic acid polymerase activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase